EU-PEARL - Nov 2019

Project title:
EU-PEARL – EU-Patient Centric Clinical Trial Platforms

Project leaders:
Janssen Pharmaceutica NV, project coordinator Fundacio hospital Universitari Vall D’Hebron Institut de Recerca

WP7 Neurofibromatosis leader:
Dr. Rianne Oostenbrink, ErasmusMC

Project description:
This is a strategic alliance between the public and private sectors to improve and accelerate drug development processes and transforming the way how clinical trials are conducted by developing a common framework for platform clinical trials. Neurofibromatosis (NF1, NF2 and Schwannomatosis) is one of the four diseases included in this project and covered by work package 7. In this project we aim to identify high priority complications in NF for what trials need to be developed for; we develop a general protocol for longitudinal history study and a master protocol for platform trials in NF; and we will build a clinical network of NF sites for future studies.

Five ERN GENTURIS Full Members are partners in Work Package 7. NF Patients United (NFPU, the European Neurofibromatosis umbrella patient association) is  included as associated collaborator.

Start date: November 2019

Duration: 42 months

Funder: This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853966. 

Link study page: https://eu-pearl.eu